What is the interaction between diphenhydramine (Benadryl) and eszopiclone (Lunesta)?

Avoid Combining Benadryl and Lunesta Due to Additive CNS Depression

Do not routinely combine diphenhydramine (Benadryl) with eszopiclone (Lunesta) due to the risk of additive central nervous system (CNS) depression, which can lead to excessive sedation, cognitive impairment, falls, and next-day psychomotor dysfunction.

The Core Problem: Pharmacodynamic Interaction

While the FDA label for Lunesta does not specifically list diphenhydramine as having a direct pharmacokinetic interaction with eszopiclone 1, both medications work through CNS depressant mechanisms that are additive when combined:

• Eszopiclone acts on GABA-A receptors to produce sedation 1
• Diphenhydramine causes sedation through H1-receptor antagonism with significant anticholinergic effects

When used together, these mechanisms compound to create:

• Enhanced sedation beyond therapeutic intent
• Increased risk of cognitive impairment and confusion
• Greater fall risk, particularly in elderly patients
• Prolonged next-day impairment affecting driving and daily function

Clinical Guidelines Explicitly Discourage Diphenhydramine for Insomnia

The American Academy of Sleep Medicine (2017) specifically recommends AGAINST using diphenhydramine for insomnia treatment 2. This is critical context—diphenhydramine should not be the sleep aid of choice in the first place, making combination therapy even less justifiable.

The guideline suggests:

• Use eszopiclone alone for sleep onset and maintenance insomnia 2
• Avoid diphenhydramine due to insufficient evidence of efficacy and concerning side effect profile 2

The American College of Physicians (2016) similarly found insufficient evidence supporting diphenhydramine while confirming eszopiclone's efficacy 3.

Specific Risks in Vulnerable Populations

Elderly Patients (≥65 years)

• Eszopiclone exposure increases 41% with prolonged half-life (~9 hours vs 6 hours) 1
• Maximum dose should not exceed 2 mg in elderly 1
• Diphenhydramine carries high anticholinergic burden associated with delirium, dementia risk, and falls 3
• The combination dramatically amplifies fall risk and cognitive impairment

Patients with Hepatic Impairment

• Eszopiclone exposure doubles in severe hepatic impairment 1
• Maximum dose 2 mg in this population 1
• Adding diphenhydramine further increases CNS depression risk

Pharmacokinetic Considerations

Diphenhydramine is a CYP2D6 inhibitor 4, 5, but eszopiclone is metabolized primarily by CYP3A4 and CYP2E1 1. Therefore, there is no significant pharmacokinetic interaction between these drugs—the concern is purely pharmacodynamic (additive CNS effects).

However, when eszopiclone was studied with olanzapine (another CNS depressant), a pharmacodynamic interaction on psychomotor function was detected despite no pharmacokinetic changes 1. This parallels the expected interaction with diphenhydramine.

Clinical Algorithm for Managing This Scenario

If a patient is taking both medications:

1. Assess the indication for each drug:

   • If diphenhydramine is for allergies → switch to non-sedating antihistamine (cetirizine, loratadine, fexofenadine)
   • If diphenhydramine is for sleep → discontinue it entirely, as eszopiclone is superior and guideline-recommended 2

2. If eszopiclone alone is insufficient:

   • Optimize eszopiclone dosing (2-3 mg in non-elderly, 1-2 mg in elderly) 2, 1
   • Consider cognitive behavioral therapy for insomnia (CBT-I) as first-line
   • If additional pharmacotherapy needed, consider ramelteon or low-dose doxepin (3-6 mg) per guidelines 2

3. Never intentionally prescribe both together for insomnia management

Common Pitfalls to Avoid

• Don't assume OTC = safe: Patients often don't report diphenhydramine use because it's over-the-counter. Always ask specifically about OTC sleep aids and antihistamines
• Don't underestimate anticholinergic burden: Diphenhydramine's anticholinergic effects (dry mouth, urinary retention, confusion) add to the CNS depression risk
• Don't ignore next-day effects: The combination can impair driving ability and increase accident risk the following day 3
• Don't forget about tolerance: Recent evidence suggests diphenhydramine may be effective for acute insomnia 6, but tolerance develops rapidly, making chronic use problematic

Bottom Line for Practice

Eszopiclone should be used as monotherapy for insomnia 2, 3. Diphenhydramine adds no therapeutic benefit and substantially increases harm risk through additive CNS depression. If a patient presents taking both, systematically eliminate the diphenhydramine while optimizing eszopiclone dosing or transitioning to evidence-based alternatives.